Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Informed consent from patient or legal representative.~2. Male or female, aged ≥ 18 years;~3. Laboratory confirmation of 2019-nCoV infection by reverse-transcription polymerase chain reaction (RT-PCR) from any diagnostic sampling source;~4. Signs of respiratory failure requiring oxygen therapy~5. Hospitalized for up to 36h with non-invasive ventilation~6. Negative result for pregnancy test (if applicable).~Exclusion Criteria:~1. Participating in another RCT in the past 12 months;~2. Known allergy to nitazoxanide~3. Severely reduced LV function;~4. Severely reduced renal function;~5. Pregnancy or breast feeding;~6. Use of hydroxychloroquine and/or azithromycin in the past 15 days;~7. Any other clinical condition which, in the opinion of the principal investigator, would not allow safe completion of the protocol and safe administration of the investigational products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- nitazoxanide (Type: EXPERIMENTAL): Patients will receive nitazoxanide 600 mg BID for 7 days.
- Placebo (Type: PLACEBO_COMPARATOR): Patients will receive placebo BID for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).